JMP Securities Life Sciences Conference
Monday, May 15, 2023 3:00 PM EDT
Q1 2023 Ocular Therapeutix, Inc. Earnings Conference Call
Monday, May 08, 2023 4:30 PM EDT
Cowen’s 43rd Annual Healthcare Conference
Tuesday, March 07, 2023 1:30 PM EST

Corporate Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery and the treatment of ocular itching associated with allergic conjunctivitis...

Data Provided by Refinitiv. Minimum 15 minutes delayed.